The Private Insurer Response to Advanced Health Care Technology The Case of Organ Transplants
With advances in medical skill and technology inevitably accompanied by a blur of media attention, organ transplants are increasingly regarded as accepted therapeutic interventions for a variety of degenerative diseases. Although the number of the nation’s transplant operations remains relatively small, enough are being performed, and long waiting lists indicate considerably more could be performed, to warrant classification of many as therapeutic and no longer experimental. For insurers and all health-care consumers, the critical question here is: Who will pay?
KeywordsPrivate Health Insurance Health Insurer Private Insurer Life Insurance Company Medical Technology Assessment
Unable to display preview. Download preview PDF.
- American Council of Life Insurance, 1984, Life Insurance Fact Book, HIAA, Washington, D.C.Google Scholar
- Health Insurance Association of America, 1985a, Organ Transplants and Their Implications for the Health Insurance Industry, Public Relations Division, HIAA, Washington, D.C.Google Scholar
- Health Insurance Association of America, 1985b, Source Book of Health Insurance Data, 1984–1985, HIAA Public Relations Division, HIAA, Washington, D.C.Google Scholar
- Health Insurance Association of America, 1985e, HIAA Survey of Coverage for Organ and Tissue Transplant Google Scholar
- Recipients Under Group Comprehensive and Major Medical Expense Plans, Other Than CollectivelyGoogle Scholar
- Bargained Plans, HIAA Research and Statistical Bulletin No. 2–85, HIAA, New York.Google Scholar
- Health Insurance Association of America, 1987, Source Book of Health Insurance Data,1986–1987, HIAAGoogle Scholar
- Public Relations Division, HIAA, Washington, D.C.Google Scholar
- Huebner, S. S., and Black, K., Jr., 1982, Life Insurance, Prentice-Hall, Englewood Cliffs, New Jersey.Google Scholar